Dpt. Of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma De Barcelona, Spain.
Virulence. 2021 Dec;12(1):444-469. doi: 10.1080/21505594.2021.1871823.
Owing to the recent outbreak of Coronavirus Disease of 2019 (COVID-19), it is urgent to develop effective and safe drugs to treat the present pandemic and prevent other viral infections that might come in the future. Proteins from our own innate immune system can serve as ideal sources of novel drug candidates thanks to their safety and immune regulation versatility. Some host defense RNases equipped with antiviral activity have been reported over time. Here, we try to summarize the currently available information on human RNases that can target viral pathogens, with special focus on enveloped single-stranded RNA (ssRNA) viruses. Overall, host RNases can fight viruses by a combined multifaceted strategy, including the enzymatic target of the viral genome, recognition of virus unique patterns, immune modulation, control of stress granule formation, and induction of autophagy/apoptosis pathways. The review also includes a detailed description of representative enveloped ssRNA viruses and their strategies to interact with the host and evade immune recognition. For comparative purposes, we also provide an exhaustive revision of the currently approved or experimental antiviral drugs. Finally, we sum up the current perspectives of drug development to achieve successful eradication of viral infections.
由于 2019 年冠状病毒病(COVID-19)的爆发,开发有效和安全的药物来治疗目前的大流行并预防未来可能出现的其他病毒感染迫在眉睫。由于其安全性和免疫调节多功能性,我们自身先天免疫系统的蛋白质可以作为新型药物候选物的理想来源。随着时间的推移,已经报道了一些具有抗病毒活性的宿主防御 RNase。在这里,我们试图总结目前可用于靶向病毒病原体的人类 RNase 的信息,特别关注包膜单链 RNA(ssRNA)病毒。总的来说,宿主 RNase 可以通过多种策略联合对抗病毒,包括病毒基因组的酶靶标、识别病毒独特的模式、免疫调节、控制应激颗粒形成以及诱导自噬/细胞凋亡途径。该综述还详细描述了代表性的包膜 ssRNA 病毒及其与宿主相互作用和逃避免疫识别的策略。为了比较的目的,我们还提供了目前批准或实验性抗病毒药物的详尽修订版。最后,我们总结了药物开发的当前观点,以实现成功根除病毒感染。